Unleashing the immune response to treat cancer.
Business Model:
Revenue: $0
Employees: 1-10
Address: 4320 Forest Park Avenue Suite 304 St.
City: Louis
State: MO
Zip: 63108
Country: US
Unleash IO develops oncolytic immunotherapy products shown to be highly specific and efficacious in animal models and human tissue samples. Unleash IO’s leading product, UIO-512, is an oncolytic adenovirus that targets both malignant cells and tumor-associated stroma cells. UIO-512 is armed with GM-CSF, a potent immune-modulatory cytokine, triggering an immune response towards the tumor. UIO-512 lead indication is in ovarian cancer, follow on indications include other solid tumors such as glioblastoma, melanoma and pancreatic cancer. Promising pre-clinical results in animal models and fresh human samples of ovarian cancers as well as in melanoma were published in top ranked peer-reviewed publications. Unleash IO is raising $3.5 M to conduct a phase I/II clinical trial in ovarian cancer with oncolytic immunotherapy UIO-512.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 8/2017 | Grant | 1 | - |
Skandalaris Center for Interdisciplinary Innovation and Entrepreneurship Skandalaris Center for Interdisciplinary Innovation and Entrepreneurship |
2/2018 | Equity | 1 | $3M |
Oncolys BioPharma Oncolys BioPharma |
2/2016 | Equity | - | 2/2016 | Equity | - |
BioGenerator BioGenerator |
8/2017 | Grant | 1 | - |
Skandalaris Center for Interdisciplinary Innovation and Entrepreneurship Skandalaris Center for Interdisciplinary Innovation and Entrepreneurship |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|